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Progress Notes 
A Report from the Parkinson's Disease Center at Boston University Medical Center August 1992 
FROM THE EDITOR 
By the time this newsletter reaches you, it probably wiU be midsummer. I am 
happy to report we have had a very busy and successful year at the Informa-
tion and Referral Center here at Boston University Medical Center. Last fall, 
the center organized what turned out to be a very successful Support Croup 
Leaders Conference. Forty group leaders met at the Sheraton Tara in Brain-
tree, Mass., for a day of sharing. Special guests included Kathryn Cullen, R.N., 
M.S., and John Curtain. Ms. Cullen is the center coordinator at Roger Wil-
liams Hospital in Providence, R.I. She did a wonderful job describing the 
many roles a Parkinson support group performs. Mr. Curtain, representing 
Sandoz Pharmaceuticals, did a presentation on PATH (a patient-education pro-
gram for patients and families that was developed by Sandoz). 
In June of this year, the center co-hosted a Parkinson Symposium with the 
Maine Chapter of the APDA. Two hundred individuals met on Saturday, June 
12, in Bangor, Maine. Blaine and Clenna Atwood, with the help of many, or-
ganized the event. Speakers included Robert Feldman, M.D., George Wright, 
M.D., KennetkSalmon, R.P.T., Linda Perry, R.N., M.Ed., and the Atwoods. It 
was a pleasure meeting those from the Northem New England area and from 
parts of Canada. 
A local symposium is being planned for the latter part of fall this year. More 
information soon wiU be available. Enjoy the rest of the summer. 
Sincerely, 
Cathi Thomas, R.N., M.S. 
Parkinson Day 
Program Update 
by Linda Perry R.N., M.Ed. 
Twice a week, the Parkinson's Day 
Program at Boston University Medical 
Center holds sessions aimed at assist-
ing in the management of common 
problems experienced by individuals 
(including family members) affected by 
Parkinson's disease. 
As a component of the outpatient 
treatment plan, the sessions were spe-
cifically designed to allow closer physi-
cian/nurse monitoring of the patients' 
medication response over a six-hour 
period, and provide education and sup-
port to patients, family members, and 
caregivers. We recently have added a 
second part of the session. 
Part 1 provides an overview of 
Parkinson's disease, information on 
medication, supportive therapy and 
current treatment modalities. 
continued on page 2 
Research News from Boston University Medical Center 
Several new research studies are under 
way at the Department of Neurology 
of Boston University Medical Center. 
i The first study will evaluate 
the efficacy of an experimental drug 
called Ropinirole in early Parkinson's 
disease. Individuals who participate 
must be on no medication for Parkin-
son's disease, or just selegiline 
(Eldepryl). Ropinirole is a dopamine 
agonist (see Medical Update, page 3). 
M The second study wiU look into 
the effects of a special diet on Parkin-
son's disease. The diet, which was de-
veloped at Interneuron Pharmaceuti-
cals, will be utilized on patients with 
"wearing off" and/or dyskinesias. 
The third study will evaluate 
balance problems associated with 
Parkinson's disease. The study will 
take place at Braintree Hospital, and 
the principal investigator is Jules Fried-
man, M.D., a neurologist with exper-
tise in this area. Robert Feldman, 
M.D., and Marie Saint-Ffrlaire, M.D., 
will assist with this project. 
Finally, data collection is almost 
complete on the nursing study "Manag-
ing the Trajectory of Care." We expect 
to enroU approximately 25 more pa-
tients. This study is being conducted 
by Ellen Mahoney, D.N.S., a 
faculty member at Boston College 
School of Nursing, Linda Perry, and 
Cathi Thomas. 
If you would like more information on 
these studies, please call 617-266-1565. 
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Day Program 
continued from page 1 
Part 2 focuses on problem solving, 
coping mechanisms and stress man-
agement. SmaU group discussion cen-
ters around the impact of the diagno-
sis and changes that occur as the dis-
ease progresses. The discussion also 
focuses on the use of appropriate cop-
ing strategies to help the patient and 
family deal effectively with their 
problems. Stress management tech-
niques are introduced and include im-
agery tapes that were developed by 
Dr. Peter Mosbach, BUMC psycholo-
gist, concepts from Dr. David Bum's 
Peeling Good Handbook, and Dr. Ar-
lin Brown's relaxation response audi-
otapes. 
The Parkinson's Day Program is 
directed by Dr. Marie Saint-Hilaire, 
who specializes in the treatment of 
movement disorders, and is coordi-
nated by Linda Perry, R.N., M.Ed. 
Special consultation with specific 
therapies can be arranged with ad-
vanced notice. 
For additional information, please 
call 617-266-1565. 
Support Group 
News 
During the past year, three new sup-
port groups have been established. 
The first group, which just cele-
brated a one-year anniversary, is the 
"Young Parkinson Support Group." 
The group has grown tremendously 
and has had a positive impact on 
those affected by Parkinson's dis-
ease. Ken Bernstein organized the 
group and currently serves as the 
president of the newly formed 
YPSG/APDA chapter. Meetings are 
held monthly at Newton-Wellesley 
Hospital. For further information, 
please call Ken at 617-527-2803. 
ft ^  7 > ' 
Walkathoners listen as Ken Bernstein reads a proclamation from Governor William 
Weld about the seriousness of Parkinson's disease. 
Mass. Chapter News 
by Jeanne McCarthy 
Once again, we have completed a successful walkathon to raise money for 
Parkinson's disease. On Saturday, May 16, many old faces and lots of new 
ones arrived at the Cleveland Circle Reservoir in Brookline, Mass., to 
pledge their support for Parkinson's research. The day started with clouds 
and rain showers, but within an hour, the sun was shining. We collected 
$4,737 on site, with many other pledges to be sent to the national office. 
Support groups really were the key to this year's success. The walk 
would not have been possible without the efforts of many of the groups, 
and 1 would like to especially thank the Norwood Parkinson Support 
group, the Young Parkinson Support Group, the Southwood Parkinson Sup-
port Group, the Newton Wellesley Support Group and the South Shore 
Support Group. Many people were unable to walk, but were able to volun-
teer in other ways. Ken Bernstein, this year's recipient of the Massachu-
setts Chapter award, read a proclamation from Governor William Weld rec-
ognizing the seriousness of Parkinson's disease. 
On the same day, the Cape Cod Support Group also held a very success-
ful walk, organized by Helen Perreult. Group members, their families and 
friends gathered at the Brewster Candy Store for their five-mile journey. 
Special thanks go to our Walkathon supporters: Boston University 
Medical Center/The University Hospital; Coolidge Corner Clubhouse,- The 
Hood Company; International Ice Cream Distributors; John Hancock Fi-
nancial Services; Trophies and Awards; The Bishop Family; John Berardi; 
Ken Bernstein; Nick's Comedy; Nunsense; Dr. and Mrs. Robert Feldman,-
Sandoz Pharmaceuticals,- Stop and Shop Inc.; and Dick Goldstein. 
continued on page 3 
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MEDICAL UPDATE: 
The Use of Dopamine 
Agonists in Parkinson's 
Disease 
by Marie Saint-Hilaire, M.D. 
The signs and symptoms of Parkin-
son's disease are primarily caused by 
a decrease of Dopamine in the brain. 
Thus, the basis of treatment is to re-
plenish the brain with dopamine. 
This is best accomplished by admin-
istering levodopa which, when enter-
ing the brain, is transformed into 
dopamine. Levodopa (usually given 
in the form of Sinemet), is the most 
effective antiparkinson medication. 
However, long-term treatment with 
Sinemet usually is associated with 
such significant complications as ab-
normal involuntary movements and 
fluctuations in mobility (on-off). 
Other medications have been devel-
oped to prevent or alleviate these 
complications. Dopamine agonists 
are important therapeutic options to 
deal with complications of levodopa 
therapy. 
Dopamine agonists bypass the de-
generating neurons of the substantia 
nigra and act directly on the dopa-
mine receptors in the brain. They do 
not need to be converted into dopa-
mine as levodopa does, and they are 
more stable and longer-acting than 
levodopa. Dopamine agonists were 
first used for treating advanced 
Parkinson's disease; now they are 
also used early in the course of the 
disease with or without treatment 
with levodopa (Sinemet). 
In the United States two dopa-
mine agonists. Bromocriptine (Par-
lodel) and Pergolide (Permax) have 
been approved by the FDA and are 
widely used. Bromocriptine, which 
has been used since the 1970's, is 
helpful when added to levodopa in 
patients with wearing-off and dyski-
nesia (involuntary movements). It de-
creases fluctuations in mobility and 
frequently allows the patient to take 
less levodopa. Studies have demon-
strated that the early introduction of 
bromocriptine can lessen the long-
term complications of levodopa ther-
apy. It is now used early in treat-
ment when patients are still on a 
low dose of levodopa (Sinemet). Pa-
Support Group News 
continued from page 2 
The second group, under the direction of Sharon Feccia, meets monthly (third 
Wednesday of the month) at the Milford-Whitinsville Hospital. Thanks to 
Sharon's efforts, more than 70 people attended the initial meeting. Dr. William 
Tosches, a neurologist and chief of staff at the hospital, gave a comprehensive 
overview of Parkinson's disease. Dr. Tosches wiU be available as a medical con-
sultant for the group. For information, please call 508-473-1190. The third group 
meets in Martha's Vineyard at the Council of Aging. The group was organized by 
Jane McCrath and already has attracted eleven members. For further informa-
tion please call 508-696-4205. The center wishes much success to these groups. 
Leadership position available. Joan and Frank Engstrom have stepped 
down as leaders of the Southwood Parkinson Support Croup, as they have relo-
cated out West. Mrs. Marie Melchen will temporarily organize the meetings, but 
is looking for an individual or individuals to assume leadership. If you are inter-
ested, please call 617-638-8466 as soon as possible. 
Change of Contact Person, 
Cape Cod Parkinson Support Group 
Contact: Frederick Lawton 
76 Wampanoag Trail 
Dennis, MA 02638 
508-385-2565 
tients who use a combination of low-
dose levodopa and bromocriptine de-
velop less dyskinesias and motor fluc-
tuations than do patients on high 
doses of levodopa alone. 
Bromocriptine also has been 
shown to be an effective medication 
in untreated patients, who also are 
not taking levodopa. Eventually, 
however, most patients will need to 
start levodopa treatment as the symp-
toms worsen. 
Bromocriptine is available in 
2.5mg tablets and 5mg capsules. 
Daily doses vary from patient to pa-
tient but can range from 1.25mg per 
day to as high as 70mg. per day (al-
though in rare instances). Side effects 
include low blood pressure, confu-
sion, hallucinations and nausea. Pa-
tients usually start with a very low 
dose to avoid these side effects. 
More recently, pergolide (Permax) 
has been approved. Its indication are 
the same as bromocriptine. Pergol-
ide is more potent than bromo-
criptine because it stimulates both 
D l and D2 receptors. The side ef-
fects of pergolide include nausea, con-
fusion, hallucinations and decrease 
in blood pressure. Some studies have 
shown that patients who do not toler-
ate bromocriptine may better toler-
ate pergolide and visa-versa. Pergol-
ide is most often used in patients 
who did not tolerate bromocriptine 
or in patients with severe fluctua-
tions who do not respond to high 
doses of bromocriptine. Pergolide is 
available in 0.05mg, 0.25mg and Img 
tablets. The standard dosage is Img, 
three times a day, but some patients 
need lower or higher doses. As with 
bromocriptine, the dose is slowly in-
creased. 
Other dopamine agonists are be-
ing used and studied mainly in 
Europe or on an experimental basis 
in the United States. They include 
hsuride and apomorphine. Lisuride 
can be given as subcutaneous infu-
sion (needle or catheter under the 
skin) through a pump, similar to in-
sulin infusions for diabetics. It does 
significantly improve fluctuations 
but can cause severe confusion. 
continued on page 4 
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Dopamine Agonists 
continued from page 3 
Apomorphine was the earliest 
dopamine agonist used in Parkinson's 
disease, but was abandoned because 
of such side effects as nausea and hy-
potension, and also because it only is 
more effective when given intrave-
nously. It now is used as a subcutane-
ous injection that patients can admin-
ister themselves for rapid "turn-on" 
during a disabling period. Generally, 
patients use it when in important 
situations and not on a continuous 
basis. A medication called dom-
peridone usually is used with apo-
morphine to decrease side 
effects. 
A new dopamine agonist, Ropini-
role, not yet approved by the FDA, is 
irbeing studied in many centers 
around the country. This medica-
tion will be studied at Boston Univer-
sity Medical Center starting this 
summer (see new research). 
Progress Notes is intended solely to provide you with 
information that you can discuss with your physician. 
You should not make any changes in your treatment 
without first discussing them with your physician. 
This newsletter was partially supported by a grant from Eli Lilly and Company. 
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